Background: COVID-19 represents a new challenge for all medical fields. In this observational, monocentric prevalence study, we try to clarify the relationship between COVID-19 and the population of psoriatic patients receiving therapy with biological or topical drugs, and the main goal is to evaluate whether the use of biological drugs has an influence on the prevalence of COVID-19 infection, in subjects receiving biologic drugs. Materials and method: This was an observational prevalence study with both retrospective and prospective data collection on the clinical data of patients with psoriasis, in relation to COVID-19 infection. A sample size of 180 psoriatic patients was divided into two groups: 100 psoriatic patients treated with topical therapy and 80 psoriatic patients on therapy with biological drugs. The data was collected from the medical records between 01/01/2020 and 31/05/2020 and was assessed for each patient treated in our Psoriasis Clinic. Results: Out of 180 patients, suspected COVID-19 infection was observed in 33 patients (18% overall). The prevalence of suspected COVID-19 within the two patient groups is nearly the same and no major difference in the risk of being infected is present; 17% of the patients treated with topical agents compared to 20% of those treated with biological agents. None of the patients had serious complications, needed hospitalization nor had a fatal outcome. Conclusions: Despite the limited sample size, it is safe to assume that psoriatic patients who are treated with biological drugs should not discontinue their use in the context of the current COVID-19 pandemic, since therapy with these agents do not seem to influence an infection by COVID-19. More research is absolutely crucial in order to solidify this preliminary conclusion.
LA PSORIASI DURANTE L’EPIDEMIA DI COVID 19: HA INFLUENZA LA TERAPIA CON FARMACI BIOLOGICI SULL’INFEZIONE DA COVID 19? STUDIO OSSERVAZIONALE, MONOCENTRICO DI PREVALENZA SUI DATI CLINICI ED EPIDEMIOLOGICI DI PAZIENTI PSORIASICI IN TERAPIA CON FARMACI BIOLOGICI O IN TERAPIA SOLO FARMACI TOPICI. Contesto: La COVID-19 rappresenta una nuova sfida per tutti i campi medici. In questo studio osservazionale di prevalenza, cerchiamo di chiarire la relazione tra COVID-19 e la popolazione di pazienti psoriasici sottoposti a terapia con farmaci biologici o topici, e l'obiettivo principale è di valutare se la terapia con farmaci biologici ha un'influenza sulla prevalenza dell'infezione da COVID-19, nei pazienti psoriasici che assumono tali farmaci. Materiali e metodi: È uno studio di prevalenza osservazionale con raccolta di dati retrospettivi e prospettici sui dati clinici di pazienti con psoriasi, in relazione all'infezione COVID-19. Lo studio interessa pazienti psoriasici che afferiscono all’Ambulatorio della Psoriasi presso la nostra Clinica Dermatologica. La numerosità del campione è di 180 pazienti psoriasici divisi in due gruppi: 100 pazienti psoriasici in terapia topica e 80 pazienti psoriasici in terapia con farmaci biologici. I dati sono stati raccolti dalle cartelle cliniche tra il 01/01/2020 e il 31/05/2020 e sono stati valutati per ciascun paziente. Risultati: Su un totale di 180, in 33 pazienti è stata osservata una sospetta infezione da COVID-19 (18% in totale). La prevalenza del sospetto COVID-19 all'interno dei due gruppi è quasi la stessa. Non è presente una differenza statisticamente significativa del rischio di infezione tra i gruppi: 17% per i pazienti trattati con agenti topici rispetto al 20% per quelli trattati con agenti biologici. Inoltre, nessuno dei pazienti presenta gravi complicanze, ha avuto la necessità di essere ricoverato in ospedale e nessuno non ha avuto esito fatale. Conclusioni: Nonostante le dimensioni limitate del campione, si può presumere che i pazienti psoriasici trattati con farmaci biologici non debbano interrompere il trattamento nel contesto dell'attuale pandemia di COVID-19, poiché la terapia con questi agenti non sembra influenzare un'infezione di COVID-19. Ulteriori ricerche sono assolutamente cruciali per consolidare queste osservazioni preliminare.
PSORIASIS DURING COVID-19 EPIDEMIC: DOES THERAPY WITH BIOLOGICAL DRUGS INFLUENCED COVID-19 INFECTION? OBSERVATIONAL, MONOCENTRIC, PREVALENCE STUDY ON THE CLINICAL AND EPIDEMIOLOGICAL DATA OF PSORIATIC PATIENTS TREATED WITH BIOLOGICAL DRUGS OR WITH TOPICAL DRUGS ALONE
BARAK, OREN
2019/2020
Abstract
Background: COVID-19 represents a new challenge for all medical fields. In this observational, monocentric prevalence study, we try to clarify the relationship between COVID-19 and the population of psoriatic patients receiving therapy with biological or topical drugs, and the main goal is to evaluate whether the use of biological drugs has an influence on the prevalence of COVID-19 infection, in subjects receiving biologic drugs. Materials and method: This was an observational prevalence study with both retrospective and prospective data collection on the clinical data of patients with psoriasis, in relation to COVID-19 infection. A sample size of 180 psoriatic patients was divided into two groups: 100 psoriatic patients treated with topical therapy and 80 psoriatic patients on therapy with biological drugs. The data was collected from the medical records between 01/01/2020 and 31/05/2020 and was assessed for each patient treated in our Psoriasis Clinic. Results: Out of 180 patients, suspected COVID-19 infection was observed in 33 patients (18% overall). The prevalence of suspected COVID-19 within the two patient groups is nearly the same and no major difference in the risk of being infected is present; 17% of the patients treated with topical agents compared to 20% of those treated with biological agents. None of the patients had serious complications, needed hospitalization nor had a fatal outcome. Conclusions: Despite the limited sample size, it is safe to assume that psoriatic patients who are treated with biological drugs should not discontinue their use in the context of the current COVID-19 pandemic, since therapy with these agents do not seem to influence an infection by COVID-19. More research is absolutely crucial in order to solidify this preliminary conclusion.È consentito all'utente scaricare e condividere i documenti disponibili a testo pieno in UNITESI UNIPV nel rispetto della licenza Creative Commons del tipo CC BY NC ND.
Per maggiori informazioni e per verifiche sull'eventuale disponibilità del file scrivere a: unitesi@unipv.it.
https://hdl.handle.net/20.500.14239/11703